ReviewCurrent topics in microbiology and immunology2014
Emerging roles for the FCRL family members in lymphocyte biology and disease.
Review in Current topics in microbiology and immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Genetic Association in Immunoglobulin G4-Related Disease: A Systematic Review.International archives of allergy and immunology · 2026Pooled it
- DNA methylation and gene expression signatures are associated with ataxia-telangiectasia phenotype.Scientific reports · 2020Trial
- Trial
- High-throughput characterization of the functional impact of IgG Fc glycan aberrancy in juvenile idiopathic arthritis.Glycobiology · 2017Trial
- A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states.Nature genetics · 2026Article
- SHIP-1 adapter functions mediate recruitment of FCRL1 to the BCR and inhibition of ERK.ImmunoHorizons · 2026Article
- Oral Islatravir in Macaques Decreases Lymphocytes and Monocytes and Is Associated with Immune Alterations.Pharmaceutics · 2026Article
- FCRL3 is an immunoregulatory receptor that restrains the activation of human memory T lymphocytes.The Journal of experimental medicine · 2026Article
- Emerging Roles of Fc Receptor-Like 1 in Immunotherapy of Diffuse Large B-Cell Lymphoma.Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al · 2025Article
- Human genetic variation reveals FCRL3 is a lymphocyte receptor for Yersinia pestis.Cell genomics · 2025Article
- Impacts of rs7528684 (-169T/C) onFrontiers in genetics · 2025Article
- Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Spatially Exploring RNA Biology in Archival Formalin-Fixed Paraffin-Embedded Tissues.bioRxiv : the preprint server for biology · 2024Article
- The potential of FCRL genes as targets for cancer treatment: insights from bioinformatics and immunology.Aging · 2023Article
- Evidence for Extensive Duplication and Subfunctionalization ofInternational journal of molecular sciences · 2023Article
- FCRL1 immunoregulation in B cell development and malignancy.Frontiers in immunology · 2023Review
- Upregulated Fcrl5 disrupts B cell anergy and causes autoimmune disease.Frontiers in immunology · 2023Article
- Impact of structural modifications of IgG antibodies on effector functions.Frontiers in immunology · 2023Review
- Differential expression of long non-coding RNAs underVirulence · 2022Article
- FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.Cell reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Members of the extended Fc receptor-like (FCRL) family in humans and mice are preferentially expressed by B cells and possess tyrosine-based immunoregulatory function. Although the majority of these proteins repress B cell receptor-mediated activation, there is an emerging evidence for their bifunctionality and capacity to counter-regulate adaptive and innate signaling pathways. In light of these findings, the recent discovery of ligands for several of these molecules has begun to reveal exciting potential for them in normal lymphocyte biology and is launching a new phase of FCRL investigation. Importantly, these fundamental developments are also setting the stage for defining their altered roles in the pathogenesis of a growing number of immune-mediated diseases. Here we review recent advances in the FCRL field and highlight the significance of these intriguing receptors in normal and perturbed immunobiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.